🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for Small Cell Ovarian Carcinoma

Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies NCT04282044Phase 13 sites📍 Scottsdale📍 La Jolla📍 Stanford BioEclipse Therapeutics · Tests: CRX100 suspension for infusion, Fludarabine, Cyclophosphamide Clinical Utility of ctDNA in Detecting Resistance Mechanisms and Delivering Precision Medicine to Cancer Patients NCT07673861NA1 site📍 London Royal Marsden NHS Foundation Trust · Tests: Marsden360 ctDNA test and GTAB review 18F-T2 PET/CT Imaging for CAIX Positive Solid Tumors NCT07557225NA1 site📍 Beijing Peking University First Hospital · Tests: 18F-T2 PET/CT A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors NCT07749586Phase 1, Phase 24 sites📍 New York📍 Huntersville📍 San Antonio Arvinas Inc. · Tests: ARV-6723, Pembrolizumab, SOC Study of MT-302 in Adults With Advanced or Metastatic Epithelial Tumors NCT05969041Phase 16 sites📍 Darlinghurst📍 Randwick📍 Westmead Myeloid Therapeutics · Tests: MT-302 (A) Addition of Pembrolizumab to the Standard of Care Chemotherapy in Patient With SCCOHT NCT04602377Phase 213 sites📍 Angers📍 Angers📍 Besançon ARCAGY/ GINECO GROUP · Tests: Pembrolizumab 25 MG/ML [Keytruda] A Phase 1 Study of LNCB74 in Advanced Solid Tumors NCT06774963Phase 114 sites📍 Newport Beach📍 Edgewood📍 Boston NextCure, Inc. · Tests: LNCB74 A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors NCT04895709Phase 1, Phase 247 sites📍 Clovis📍 Los Angeles📍 Newport Beach Bristol-Myers Squibb · Tests: BMS-986340, BMS-936558-01, Docetaxel, Pumitamig Anti-NY-ESO-1 TCR-Gene Engineered Lymphocytes Given by Infusion to Patients With NY-ESO-1 -Expressing Metastatic Cancers NCT05296564Phase 1, Phase 21 site📍 Jerusalem Hadassah Medical Organization · Tests: CYCLOPHOSPHAMIDE and FLUDARABIN, Cyclophosphamide, HBI 0201-ESO TCRT, Aldesleukin Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors NCT05985655Phase 1, Phase 215 sites📍 Los Angeles📍 Grand Rapids📍 New York Exscientia AI Ltd., a wholly owned subsidiary of Recursion … · Tests: GTAEXS617, SoC A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors NCT07488676Phase 1, Phase 221 sites📍 Birmingham📍 Los Angeles📍 Miami Astellas Pharma Global Development, Inc. · Tests: ASP546C Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of MT-304 in Adults With Advanced HER2-Expressing Solid Tumors NCT07334119Phase 17 sites📍 Darlinghurst📍 Randwick📍 Waratah Myeloid Therapeutics · Tests: MT-304, MT-304 + Nivolumab A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types NCT07503808Phase 115 sites📍 Denver📍 Sarasota📍 Detroit IDEAYA Biosciences · Tests: IDE034 A Study to Evaluate the Safety, Tolerability, and Efficacy of Escalating Doses of BMS-986463 in Participants With Select Advanced Malignant Tumors. NCT06476808Phase 117 sites📍 Los Angeles📍 Los Angeles📍 Hackensack Bristol-Myers Squibb · Tests: BMS-986463 18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection NCT06503146Phase 21 site📍 Bethesda National Cancer Institute (NCI) · Tests: [18F]FAPI-74, [18F]FDG Romiplostim N01 Plus ATRA for Persistent Isolated Chemotherapy-Induced Thrombocytopenia After Complete Remission of Gynecologic, Breast, or Lung Solid Tumors NCT07586826Phase 21 site📍 Beijing Peking University People's Hospital · Tests: Romiplostim N01, All-trans retinoic acid Assessment of Compliance With Monitoring Conducted by a Physician in Person or by a Nurse in Remote Monitoring NCT05500391Phase 23 sites📍 Amiens📍 Caen📍 Lille Centre Oscar Lambret · Tests: Oncological Follow-up A Study of KIVU-107 in Participants With Locally Advanced or Metastatic Solid Tumors NCT07229313Phase 17 sites📍 Santa Monica📍 New Have📍 Camperdown Kivu Bioscience Inc. · Tests: KIVU-107 Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors NCT06239194Phase 1, Phase 26 sites📍 Denver📍 Miami📍 Boston ModeX Therapeutics, An OPKO Health Company · Tests: MDX2001 A Study to Test the Safety, Tolerability and Effect of ZI-MA4-1 for Patients With Locally Advanced or Metastatic Solid Malignancies NCT07613723Phase 12 sites📍 London📍 Manchester Zelluna Immunotherapy AS · Tests: ZI-MA4-1 (TCR-NK cells), Cyclophosphamide, Fludarabine Phase I Study of SYS6043 in Patients With Advanced/Metastatic Solid Tumors NCT07424547Phase 15 sites📍 Plantation📍 Plantation📍 Austin Conjupro Biotherapeutics, Inc. · Tests: SYS6043 A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer NCT05902988Phase 1, Phase 214 sites📍 Los Angeles📍 Newport Beach📍 Aurora Volastra Therapeutics, Inc. · Tests: VLS-1488 A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors NCT05914116Phase 1, Phase 2107 sites📍 Tucson📍 Los Angeles📍 Los Angeles DualityBio Inc. · Tests: DB-1311, Lopinavir and Ritonavir Tablets, itraconazole, Enzalutamide, Abiraterone Integrated Cancer Repository for Cancer Research NCT02012699n/a42 sites📍 Greenwood Village📍 Manchester📍 Daytona Beach University of Nebraska ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation NCT05059444n/a57 sites📍 Birmingham📍 Chandler📍 Hot Springs Guardant Health, Inc. · Tests: Guardant Reveal A Study of MGC026 in Participants With Advanced Solid Tumors NCT06242470Phase 112 sites📍 Los Angeles📍 Grand Rapids📍 Lake Success MacroGenics · Tests: MGC026 Dose Escalation, MGC026 Dose for Expansion A Study of MT-4561 in Patients With Various Advanced Solid Tumors NCT06943521Phase 1, Phase 26 sites📍 Los Angeles📍 Grand Rapids📍 Columbus Tanabe Pharma America, Inc. · Tests: MT-4561 Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer NCT03412877Phase 21 site📍 Bethesda National Cancer Institute (NCI) · Tests: Cyclophosphamide, Fludarabine, Aldesleukin, Individual Patient TCR-Transduced PBL, Pembrolizumab (KEYTRUDA(R)) Evaluation of XYA02 in Patients With Advanced Solid Tumors NCT07670312Phase 1, Phase 25 sites📍 Sydney📍 Sydney📍 Melbourne XYone Therapeutics, Inc · Tests: XYA02 AOH1996 for the Treatment of Refractory Solid Tumors NCT05227326Phase 13 sites📍 Scottsdale📍 Duarte📍 Long Beach City of Hope Medical Center · Tests: PCNA Inhibitor AOH1996
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy